Publications prior to 2010 are credited to the Cancer Vaccine Consortium, the former name of the Cancer Immunotherapy Consortium.

Peer Reviewed Journals

• Wolchok J. et al. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clin Cancer Res 2009;15(23):7412–20. International collaborations between academic and industry define a new set of response criteria to evaluate the activity of immunotherapeutic agents in clinical trial.
• "Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells" published in Cancer Immunology, Immunotherapy (5 November 2009) [OPEN ACCESS]. The serum task force results demonstrate compellingly that serum–free media perform as well as qualified medium/serum combinations, independent of the applied SOP. Recovery and viability of cells are largely unaffected by serum–free conditions even after overnight resting. Furthermore, one serum–free medium was identified that appears to enhance antigen–specific IFNgamma–secretion.
• "Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium" published in Cancer Immunology, Immunotherapy (4 March 2009). Results from a multicenter HLA-peptide multimer proficiency panel (MPP) with a group of 27 laboratories to assess the performance of the assay.
• "Lessons from randomized phase III studies with active cancer immunotherapies – Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)" published in Vaccine 25:B97-B109 (27 September 2007).
• "Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)" published in Cancer Immunology, Immunotherapy (26 August 2007) [OPEN ACCESS]. Describes CVC’s ImmunoAssay Proficiency Panel Program, which develops harmonization guidelines for the industry. This program was initiated with an international Elispot proficiency panel composed of 36 laboratories in 2005, followed by a second panel of 29 participating laboratories in 2006.
• "Toward the harmonization of immune monitoring in clinical trials: Quo vadis?" published in Cancer Immunology, Immunotherapy (26 August 2007) [OPEN ACCESS]. A joint position commentary by the CVC and the C-IMT (Association for Immunotherapy of Cancer, an affiliate of the CVC) supporting the findings of both organizations. The paper calls for harmonization to provide markers for developing new therapies in clinical trials, thus helping improve the clinical success of immunotherapies and bringing them to patients more expeditiously.
• "A Clinical Development Paradigm for Cancer Vaccines and Related Biologics" published in Journal of Immunotherapy 30:1-15 (January 2007). This is the report of the Cancer Vaccine Clinical Trial Working Group, a joint initiative of the Cancer Vaccine Consortium and the International Society for Biological Therapy of Cancer.  

Consortium E-Newsletter

• Cancer Immunotherapy Today is a free e-publication from the Cancer Immunotherapy Consortium, including community news, announcements, and reports on CIC activities

You may also be interested in reading publications from researchers involved in the CRI/LICR Cancer Vaccine Collaborative. Some of these papers are available in the free online journal, Cancer Immunity, the official publication of the Academy of Cancer Immunology.

Back to Cancer Immunotherapy Consortium main page